News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
374,391 Results
Type
Article (25680)
Company Profile (69)
Press Release (348642)
Section
Business (104165)
Career Advice (445)
Deals (16861)
Drug Delivery (43)
Drug Development (47491)
Employer Resources (47)
FDA (12225)
Job Trends (8416)
News (185685)
Policy (19382)
Tag
Academia (1730)
Allergies (50)
Alliances (26543)
Alzheimer's disease (717)
Approvals (12191)
Artificial intelligence (86)
Bankruptcy (136)
Best Places to Work (6833)
Breast cancer (87)
Cancer (688)
Cardiovascular disease (73)
Career advice (406)
Cell therapy (117)
Clinical research (39359)
Collaboration (218)
Compensation (48)
COVID-19 (1451)
C-suite (56)
Data (767)
Diabetes (98)
Diagnostics (3364)
Earnings (36025)
Events (50459)
Executive appointments (200)
FDA (12649)
Funding (187)
Gene therapy (71)
GLP-1 (319)
Government (2993)
Healthcare (12123)
Infectious disease (1496)
Inflammatory bowel disease (65)
IPO (6970)
Job creations (1836)
Job search strategy (376)
Layoffs (150)
Legal (3614)
Liver cancer (49)
Lung cancer (128)
Manufacturing (61)
Medical device (12698)
Medtech (12701)
Mergers & acquisitions (9964)
Metabolic disorders (255)
Neuroscience (887)
NextGen Class of 2024 (3924)
Non-profit (2813)
Northern California (768)
Obesity (147)
Opinion (62)
Patents (54)
People (34095)
Phase I (11242)
Phase II (17052)
Phase III (14001)
Pipeline (268)
Postmarket research (1665)
Preclinical (3516)
Radiopharmaceuticals (156)
Rare diseases (104)
Real estate (2838)
Regulatory (13669)
Research institute (1598)
Southern California (677)
Startups (2116)
United States (7527)
Vaccines (287)
Weight loss (107)
Date
Today (25)
Last 7 days (388)
Last 30 days (2013)
Last 365 days (20102)
2024 (18418)
2023 (22736)
2022 (30680)
2021 (32986)
2020 (32195)
2019 (28414)
2018 (21812)
2017 (18906)
2016 (18111)
2015 (21194)
2014 (16024)
2013 (13241)
2012 (14349)
2011 (14622)
2010 (13181)
Location
Africa (353)
Arizona (90)
Asia (24040)
Australia (3800)
California (1683)
Canada (776)
China (169)
Colorado (91)
Connecticut (94)
Delaware (50)
Europe (46894)
Florida (292)
Georgia (73)
Illinois (227)
Indiana (136)
Kansas (67)
Maryland (422)
Massachusetts (1225)
Michigan (70)
Minnesota (179)
New Hampshire (53)
New Jersey (612)
New York (531)
North Carolina (401)
Northern California (768)
Ohio (88)
Pennsylvania (525)
South America (518)
Southern California (677)
Texas (281)
Utah (50)
Washington State (142)
374,391 Results for "kahr medical".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Myeloma Investment Fund Invests in KAHR to Explore Potential of KAHR’s Lead Immunotherapy Drug Candidate for the Treatment of Multiple Myeloma
KAHR and the Myeloma Investment Fund announced that the MIF has invested in KAHR to explore the potential of DSP107, KAHR’s lead immunotherapy drug candidate, for the treatment of multiple myeloma.
November 17, 2022
·
4 min read
Drug Development
KAHR Reports Dose Escalation Results from Phase I Trial of DSP107 in Combination with anti-PD-L1 in Patients with Advanced Solid Tumors
KAHR today announced positive results from the dose escalation Phase I study of DSP107 in combination with atezolizumab (anti-PD-L1) in patients with advanced solid tumors.
May 31, 2023
·
4 min read
Business
KAHR Announces Appointment of Jennifer Minai-Azary to its Board of Directors
KAHR , a clinical-stage cancer immunotherapy company developing novel bi-functional fusion proteins, today announced the appointment of Jennifer Minai-Azary to its Board of Directors. The appointment is effective immediately.
July 11, 2022
·
2 min read
Samsung Biologics and KAHR Medical Announce Development and Manufacturing Agreement for Cancer Immunotherapy Drug Candidate
Samsung Biologics, the world’s leading contract development and manufacturing organization, signed a strategic partnership with KAHR Medical Ltd., a cancer immunotherapy company developing novel multifunctional immune-recruitment proteins.
June 2, 2021
·
3 min read
Press Releases
Tenon Medical(R) Regains Full Compliance with Nasdaq Continued Listing Requirements
October 28, 2024
·
3 min read
Drug Development
KAHR and Cancer Focus Fund Announce First Patient Dosed in Phase 1b Clinical Trial of Anti-CD47 Product Candidate DSP107 in Blood Cancers
KAHR, today announced that the first patient has been dosed in a Phase 1b clinical trial of DSP107.
February 17, 2022
·
5 min read
News
Tenon Medical(R) Announces Issuance of Three U.S. Patents
October 18, 2024
·
4 min read
Drug Development
KAHR Announces Publication of Preclinical Data Indicating Monotherapy and Combination Treatment Potential of its Investigational Anti-CD47 Fusion Protein
KAHR, today announced publication of preclinical data supporting the development of DSP107, a potential first-in-class investigational CD47x41BB targeting fusion protein designed to activate both the innate and adaptive immune systems, as a monotherapy and in combination for the treatment of cancer.
March 15, 2022
·
3 min read
Drug Development
KAHR Receives Investment from Cancer Focus Fund to Support Phase 1/2 Study of KAHR’s Lead Anti-CD47 Candidate in Blood Cancers
KAHR and Cancer Focus Fund, LP, a unique venture capital fund established in collaboration with The University of Texas MD Anderson Cancer Center to provide funding and clinical expertise to advance promising cancer therapies, announced that Cancer Focus Fund is investing $5 million to finance a clinical trial of KAHR’s lead anti-CD47 candidate, DSP107, in blood cancers.
May 26, 2021
·
5 min read
KAHR Medical to Present at Oppenheimer’s Private Life Sciences Company Call Series
KAHR Medical today announced the company’s participation in Oppenheimer’s Private Life Sciences Company Call Series taking place virtually August 17-19, 2020.
August 13, 2020
·
2 min read
1 of 37,440
Next